Cargando…

Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)

We estimated proportions of different types of diabetes, comorbidities, treatment (the use of oral glucose-lowering agents and insulin), control (hyperglycemia, dyslipidemia and hypertension) and chronic microvascular and macrovascular complications among people with diabetes presenting to the terti...

Descripción completa

Detalles Bibliográficos
Autores principales: Esteghamati, Alireza, Larijani, Bagher, Aghajani, Mohammad Haji, Ghaemi, Fatemeh, Kermanchi, Jamshid, Shahrami, Ali, Saadat, Mohammad, Esfahani, Ensieh Nasli, Ganji, Morsaleh, Noshad, Sina, Khajeh, Elias, Ghajar, Alireza, Heidari, Behnam, Afarideh, Mohsen, Mechanick, Jeffrey I., Ismail-Beigi, Faramarz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647418/
https://www.ncbi.nlm.nih.gov/pubmed/29044139
http://dx.doi.org/10.1038/s41598-017-13379-z
_version_ 1783272243582730240
author Esteghamati, Alireza
Larijani, Bagher
Aghajani, Mohammad Haji
Ghaemi, Fatemeh
Kermanchi, Jamshid
Shahrami, Ali
Saadat, Mohammad
Esfahani, Ensieh Nasli
Ganji, Morsaleh
Noshad, Sina
Khajeh, Elias
Ghajar, Alireza
Heidari, Behnam
Afarideh, Mohsen
Mechanick, Jeffrey I.
Ismail-Beigi, Faramarz
author_facet Esteghamati, Alireza
Larijani, Bagher
Aghajani, Mohammad Haji
Ghaemi, Fatemeh
Kermanchi, Jamshid
Shahrami, Ali
Saadat, Mohammad
Esfahani, Ensieh Nasli
Ganji, Morsaleh
Noshad, Sina
Khajeh, Elias
Ghajar, Alireza
Heidari, Behnam
Afarideh, Mohsen
Mechanick, Jeffrey I.
Ismail-Beigi, Faramarz
author_sort Esteghamati, Alireza
collection PubMed
description We estimated proportions of different types of diabetes, comorbidities, treatment (the use of oral glucose-lowering agents and insulin), control (hyperglycemia, dyslipidemia and hypertension) and chronic microvascular and macrovascular complications among people with diabetes presenting to the tertiary-care academic diabetes outpatient clinics in Iran. This study is the prospective analysis of data (n = 30,202) from the registry of university-affiliated adult outpatient diabetes clinics in the country during 2015–2016. The proportions of type 1 diabetes, types 2 diabetes, and other types of diabetes were 11.4%, 85.5%, and 1.3%, respectively. The frequencies of drug-naivety, use of oral agents, insulin monotherapy and insulin combination therapy were 2.9%, 60.5%, 11.5%, and 25.1%, respectively. Around 13.2%, 11.9% and 43.3% of patients with diabetes had controlled hyperglycemia, hyperlipidemia and hypertension, respectively. The proportions of retinopathy, nephropathy, peripheral neuropathy, diabetic foot, and ischemic heart disease were 21.9%, 17.6%, 28.0%, 6.2%, and 23.9%, respectively. Despite the wide availability of medications and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia and hypertension (especially for young men and old women) remains subpar. The present study further suggests that the frequencies of chronic vascular complications among patients with diabetes are relatively high in Iran.
format Online
Article
Text
id pubmed-5647418
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56474182017-10-26 Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016) Esteghamati, Alireza Larijani, Bagher Aghajani, Mohammad Haji Ghaemi, Fatemeh Kermanchi, Jamshid Shahrami, Ali Saadat, Mohammad Esfahani, Ensieh Nasli Ganji, Morsaleh Noshad, Sina Khajeh, Elias Ghajar, Alireza Heidari, Behnam Afarideh, Mohsen Mechanick, Jeffrey I. Ismail-Beigi, Faramarz Sci Rep Article We estimated proportions of different types of diabetes, comorbidities, treatment (the use of oral glucose-lowering agents and insulin), control (hyperglycemia, dyslipidemia and hypertension) and chronic microvascular and macrovascular complications among people with diabetes presenting to the tertiary-care academic diabetes outpatient clinics in Iran. This study is the prospective analysis of data (n = 30,202) from the registry of university-affiliated adult outpatient diabetes clinics in the country during 2015–2016. The proportions of type 1 diabetes, types 2 diabetes, and other types of diabetes were 11.4%, 85.5%, and 1.3%, respectively. The frequencies of drug-naivety, use of oral agents, insulin monotherapy and insulin combination therapy were 2.9%, 60.5%, 11.5%, and 25.1%, respectively. Around 13.2%, 11.9% and 43.3% of patients with diabetes had controlled hyperglycemia, hyperlipidemia and hypertension, respectively. The proportions of retinopathy, nephropathy, peripheral neuropathy, diabetic foot, and ischemic heart disease were 21.9%, 17.6%, 28.0%, 6.2%, and 23.9%, respectively. Despite the wide availability of medications and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia and hypertension (especially for young men and old women) remains subpar. The present study further suggests that the frequencies of chronic vascular complications among patients with diabetes are relatively high in Iran. Nature Publishing Group UK 2017-10-18 /pmc/articles/PMC5647418/ /pubmed/29044139 http://dx.doi.org/10.1038/s41598-017-13379-z Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Esteghamati, Alireza
Larijani, Bagher
Aghajani, Mohammad Haji
Ghaemi, Fatemeh
Kermanchi, Jamshid
Shahrami, Ali
Saadat, Mohammad
Esfahani, Ensieh Nasli
Ganji, Morsaleh
Noshad, Sina
Khajeh, Elias
Ghajar, Alireza
Heidari, Behnam
Afarideh, Mohsen
Mechanick, Jeffrey I.
Ismail-Beigi, Faramarz
Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
title Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
title_full Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
title_fullStr Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
title_full_unstemmed Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
title_short Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
title_sort diabetes in iran: prospective analysis from first nationwide diabetes report of national program for prevention and control of diabetes (nppcd-2016)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647418/
https://www.ncbi.nlm.nih.gov/pubmed/29044139
http://dx.doi.org/10.1038/s41598-017-13379-z
work_keys_str_mv AT esteghamatialireza diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT larijanibagher diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT aghajanimohammadhaji diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT ghaemifatemeh diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT kermanchijamshid diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT shahramiali diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT saadatmohammad diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT esfahaniensiehnasli diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT ganjimorsaleh diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT noshadsina diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT khajehelias diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT ghajaralireza diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT heidaribehnam diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT afaridehmohsen diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT mechanickjeffreyi diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016
AT ismailbeigifaramarz diabetesiniranprospectiveanalysisfromfirstnationwidediabetesreportofnationalprogramforpreventionandcontrolofdiabetesnppcd2016